Compass Therapeutics Reports Positive Phase 2/3 BTC Results
The company reported that tovecimig plus paclitaxel improved ORR to 18.0% versus 5.3% and median PFS to 4.7 versus 2.6 months in previously treated advanced biliary tract cancer (HR=0.44).
Compass Therapeutics published Phase 2/3 data showing tovecimig plus paclitaxel improved ORR to 18.0% vs 5.3% and median PFS to 4.7 vs 2.6 months (HR=0.44) in previously treated advanced biliary tract cancer.Material DetailsContext by AI AnalystThis is a mid-stage clinical validation step for CMPX’…